全体要約
2022年の世界の嚢胞性線維症治療薬市場は、地域別および市場セクター別に分析され、2023年から2029年の予測が示されています。アメリカ、中国、ヨーロッパの市場はそれぞれ成長が見込まれ、主要企業にはアクタビス、ロシュ、ギリアド・サイエンシズ、ノバルティス、バーテックス・ファーマシューティカルズなどが含まれます。これらの企業は2022年において市場シェアの大部分を占めています。
このレポートは、嚢胞性線維症治療薬の製品タイプ、アプリケーション、主要メーカー、地域別の市場シェアと成長機会を包括的に示しています。市場は経口および注射用の治療薬に分かれ、病院やクリニックでの使用が主なアプリケーションとして挙げられています。
関連する質問
Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals, Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics, Boehringer Ingelheim, Chiesi Farmaceutici, Corbus Pharmaceuticals, Genzyme, Insmed, Johnson & Johnson, Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, PharmaSwiss, Pharmaxis, Proteostasis Therapeutics, PTC Therapeutics, United Medical, Venus Remedies
製品セグメンテーションのトレンド, 主要企業の市場シェア, 地域別の市場成長機会
概要
このインサイトレポートは、世界の嚢胞性線維症治療薬の状況を包括的に分析し、製品セグメンテーション、企業形成、収益、市場シェア、最新の開発およびM&A活動に関連する主要なトレンドを強調しています。また、このレポートは、嚢胞性線維症治療薬のポートフォリオと能力、市場参入戦略、市場ポジション、地理的な足跡に焦点を当て、主要なグローバル企業の戦略を分析し、加速する世界の嚢胞性線維症治療薬市場におけるこれらの企業の独自の位置をより良く理解するためのものです。
このインサイトレポートでは、嚢胞性線維症薬の世界的な展望を形成する主要な市場トレンド、ドライバー、および影響因子を評価し、タイプ、アプリケーション、地域、市場規模ごとに予測を分解して新たな機会のポケットを強調しています。数百の下位から上位への質的および量的市場入力に基づいた透明な方法論により、この研究予測は、世界的な嚢胞性線維症薬の現在の状態と将来の軌道に対する非常に細やかな視点を提供します。
グローバル嚢胞性線維症薬市場の規模は、2022年のXX米ドルから2029年のXX米ドルに成長することが予測されています。また、2023年から2029年にかけてのCAGRはXX%成長すると見込まれています。
アメリカの嚢胞性線維症薬市場は、2022年のUS$ millionから2029年にはUS$ millionに増加すると推定されており、2023年から2029年の間にCAGR %の成長率を記録する見込みです。
中国の嚢胞性線維症薬市場は、2022年のXX米ドルから2029年にはXX米ドルに増加すると見込まれており、2023年から2029年までの年間平均成長率（CAGR）はXX%です。
システィックファイブローシス治療薬のヨーロッパ市場は、2022年のXX米ドルから2029年までにXX米ドルに増加する見込みであり、2023年から2029年までの間にXX%のCAGRで成長する予測です。
グローバルな主要な嚢胞性線維症薬のプレイヤーには、アクタビス、F. ホフマン・ラ・ロシュ、ギリアド・サイエンシズ、ノバルティス、バーテックス・ファーマシューティカルズ、アボット、アンテラ・ファーマシューティカルズ、アークチュラス・テラピューティクス、ベーリンガーインゲルハイムなどが含まれます。収益に関しては、2022年において世界の2大企業がほぼXX%のシェアを占めました。
このレポートは、嚢胞性線維症治療薬市場の製品タイプ、応用、主要メーカー、主要地域および国別の包括的な概要、市場シェア、成長機会を提示しています。
市場セグメンテーション
タイプ別セグメンテーション
経口嚢胞性線維症薬
注射用嚢胞性線維症治療薬
アプリケーション別のセグメンテーション
病院
クリニック
その他
この報告書では、市場を地域別に分けています。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下のプロフィールに記載されている企業は、主要な専門家からのインプットを基に選定され、企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果です。
アクタビス
F. ホフマン・ラ・ロシュ
ギリアド・サイエンシズ
ノバルティス
バーテックスファーマシューティカルズ
アボット
アンセラ製薬
アークチュラス・セラピューティクス
ボーリンガー・インゲルハイム
キエジファルマシューティクス
コルバスファーマシューティカルズ
ジェンザイム
インスメッド
ジョンソン・エンド・ジョンソン
メルク シャープ ＆ ドーム
ネオビィバイotech
ノボ・ノルディスク
ファーマスイス
ファーマクシス
プロテオスタシス・セラピューティクス
PTCセラピューティクス
ユナイテッドメディカル
ヴィーナス・レメディーズ
このレポートで扱う重要な質問
全世界の嚢胞性線維症薬市場の10年間の展望は何ですか？
嚢胞性線維症薬市場の成長を地域別および全体的に促進している要因は何ですか？
どの技術が市場と地域によって最も早い成長が期待されているか？
嚢胞性線維症薬の市場機会は、最終市場の規模によってどのように異なりますか？
嚢胞性線維症薬の種類、用途の内訳はどのようになりますか？
COVID-19及びロシア・ウクライナ戦争の影響は何ですか？
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの嚢胞性線維症治療薬、年間売上、2018年～2029年
2.1.2 嚢胞性線維症治療薬の世界市場の現状分析・将来予測、地理別、2018年、2022年および2029年
2.1.3 嚢胞性線維症治療薬の世界市場の現状分析・将来予測、国・地域別、2018年、2022年および2029年
2.2 嚢胞性線維症治療薬セグメント、タイプ別
2.2.1 オーラル嚢胞性線維症治療薬
2.2.2 注射嚢胞性線維症治療薬
2.3 嚢胞性線維症治療薬の売上、タイプ別
2.3.1 グローバルにおける嚢胞性線維症治療薬の売上・市場シェア、タイプ別（2018年～2023年）
2.3.2 嚢胞性線維症治療薬のグローバルレベニュー・市場シェア、タイプ別（2018～2023年）
2.3.3 グローバルの嚢胞性線維症治療薬、販売価格（タイプ別）（2018年～2023年）
2.4 嚢胞性線維症治療薬セグメント、用途別
2.4.1 病院
2.4.2 クリニック
2.4.3 その他
2.5 嚢胞性線維症治療薬の売上、用途別
2.5.1 グローバルの嚢胞性線維症治療薬、収益・市場シェア（用途別）（2018年～2023年）
2.5.2 嚢胞性線維症治療薬のグローバルレベニュー・市場シェア、用途別（2018～2023年）
2.5.3 グローバルの嚢胞性線維症治療薬、販売価格（用途別）（2018年～2023年）
3 グローバルにおける嚢胞性線維症治療薬、企業別
3.1 グローバルにおける嚢胞性線維症治療薬市場のブレークダウンデータ、企業別
3.1.1 グローバルにおける嚢胞性線維症治療薬の年間売上、企業別（2018年～2023年）
3.1.2 グローバルにおける嚢胞性線維症治療薬の売上・市場シェア、企業別（2018年～2023年）
3.2 グローバルにおける嚢胞性線維症治療薬の年間収益、企業別（2018年～2023年）
3.2.1 グローバルにおける嚢胞性線維症治療薬市場の収益規模、企業別（2018年～2023年）
3.2.2 グローバルにおける嚢胞性線維症治療薬市場の収益シェア、企業別（2018年～2023年）
3.3 グローバルにおける嚢胞性線維症治療薬の販売価格、企業別
3.4 嚢胞性線維症治療薬の主要メーカー、生産地域分布、販売地域、製品タイプ
3.4.1 嚢胞性線維症治療薬の主要メーカー、製品と拠点の分布
3.4.2 プレイヤーが提供している嚢胞性線維症治療薬製品
3.5 市場集中度分析
3.5.1 競合情勢分析
3.5.2 集中度レシオ（CR3、CR5、CR10）（2018年～2023年）
3.6 新製品・潜在的参入
3.7 M&A、拡大
4 嚢胞性線維症治療薬の世界市場過去推移レビュー、地理別
4.1 嚢胞性線維症治療薬の世界市場規模の過去推移、地理別（2018年～2023年）
4.1.1 グローバルにおける嚢胞性線維症治療薬の年間売上、地理別（2018年～2023年）
4.1.2 グローバルにおける嚢胞性線維症治療薬の年間収益、地理別（2018年～2023年）
4.2 嚢胞性線維症治療薬の世界市場規模の過去推移、国・地域別（2018年～2023年）
4.2.1 グローバルにおける嚢胞性線維症治療薬の年間売上、国・地域別（2018年～2023年）
4.2.2 グローバルにおける嚢胞性線維症治療薬の年間収益、国・地域別（2018年～2023年）
4.3 アメリカズにおける嚢胞性線維症治療薬の売上成長
4.4 APACにおける嚢胞性線維症治療薬の売上成長
4.5 ヨーロッパにおける嚢胞性線維症治療薬の売上成長
4.6 中東・アフリカにおける嚢胞性線維症治療薬の売上成長
5 アメリカズ
5.1 アメリカズにおける嚢胞性線維症治療薬の売上、国別
5.1.1 アメリカズにおける嚢胞性線維症治療薬の売上規模、国別（2018年～2023年）
5.1.2 アメリカズにおける嚢胞性線維症治療薬市場の収益規模、国別（2018年～2023年）
5.2 アメリカズにおける嚢胞性線維症治療薬の売上、タイプ別
5.3 アメリカズにおける嚢胞性線維症治療薬の売上、用途別
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける嚢胞性線維症治療薬の売上、地域別
6.1.1 APACにおける嚢胞性線維症治療薬の売上規模、地域別（2018年～2023年）
6.1.2 APACにおける嚢胞性線維症治療薬市場の収益規模、地域別（2018年～2023年）
6.2 APACにおける嚢胞性線維症治療薬の売上、タイプ別
6.3 APACにおける嚢胞性線維症治療薬の売上、用途別
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
6.10 中国の台湾
7 ヨーロッパ
7.1 ヨーロッパにおける嚢胞性線維症治療薬、国別
7.1.1 ヨーロッパにおける嚢胞性線維症治療薬の売上規模、国別（2018年～2023年）
7.1.2 ヨーロッパにおける嚢胞性線維症治療薬市場の収益規模、国別（2018年～2023年）
7.2 ヨーロッパにおける嚢胞性線維症治療薬の売上、タイプ別
7.3 ヨーロッパにおける嚢胞性線維症治療薬の売上、用途別
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカにおける嚢胞性線維症治療薬、国別
8.1.1 中東・アフリカにおける嚢胞性線維症治療薬の売上規模、国別（2018年～2023年）
8.1.2 中東・アフリカにおける嚢胞性線維症治療薬市場の収益規模、国別（2018年～2023年）
8.2 中東・アフリカにおける嚢胞性線維症治療薬の売上、タイプ別
8.3 中東・アフリカにおける嚢胞性線維症治療薬の売上、用途別
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 製造コスト構造分析
10.1 原料・サプライヤー
10.2 嚢胞性線維症治療薬の製造コスト構造分析
10.3 嚢胞性線維症治療薬の製造プロセス分析
10.4 嚢胞性線維症治療薬のインダストリーチェーン構造
11 マーケティング・流通・顧客
11.1 販売チャネル
11.1.1 直接チャネル
11.1.2 間接チャネル
11.2 嚢胞性線維症治療薬の流通業者
11.3 嚢胞性線維症治療薬の顧客
12 嚢胞性線維症治療薬の世界市場予測レビュー、地理別
12.1 グローバルにおける嚢胞性線維症治療薬の市場規模予測、地域別
12.1.1 グローバルの嚢胞性線維症治療薬、市場予測（地域別）（2024年～2029年）
12.1.2 グローバルの嚢胞性線維症治療薬、年間収益予測（地域別）（2024年～2029年）
12.2 アメリカズにおける予測、国別
12.3 APACにおける予測、地域別
12.4 ヨーロッパにおける予測、国別
12.5 中東・アフリカにおける予測、国別
12.6 グローバルにおける嚢胞性線維症治療薬の市場予測、タイプ別
12.7 グローバルにおける嚢胞性線維症治療薬の市場予測、用途別
13 キープレイヤー分析
13.1 Actavis
13.1.1 Actavis：企業情報
13.1.2 Actavis：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.1.3 Actavis：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.1.4 Actavis：主要事業概要
13.1.5 Actavis：直近の展開
13.2 F\. Hoffmann-La Roche
13.2.1 F\. Hoffmann-La Roche：企業情報
13.2.2 F\. Hoffmann-La Roche：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.2.3 F\. Hoffmann-La Roche：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.2.4 F\. Hoffmann-La Roche：主要事業概要
13.2.5 F\. Hoffmann-La Roche：直近の展開
13.3 Gilead Sciences
13.3.1 Gilead Sciences：企業情報
13.3.2 Gilead Sciences：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.3.3 Gilead Sciences：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.3.4 Gilead Sciences：主要事業概要
13.3.5 Gilead Sciences：直近の展開
13.4 Novartis
13.4.1 Novartis：企業情報
13.4.2 Novartis：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.4.3 Novartis：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.4.4 Novartis：主要事業概要
13.4.5 Novartis：直近の展開
13.5 Vertex Pharmaceuticals
13.5.1 Vertex Pharmaceuticals：企業情報
13.5.2 Vertex Pharmaceuticals：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.5.3 Vertex Pharmaceuticals：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.5.4 Vertex Pharmaceuticals：主要事業概要
13.5.5 Vertex Pharmaceuticals：直近の展開
13.6 Abbott
13.6.1 Abbott：企業情報
13.6.2 Abbott：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.6.3 Abbott：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.6.4 Abbott：主要事業概要
13.6.5 Abbott：直近の展開
13.7 Anthera Pharmaceuticals
13.7.1 Anthera Pharmaceuticals：企業情報
13.7.2 Anthera Pharmaceuticals：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.7.3 Anthera Pharmaceuticals：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.7.4 Anthera Pharmaceuticals：主要事業概要
13.7.5 Anthera Pharmaceuticals：直近の展開
13.8 Arcturus Therapeutics
13.8.1 Arcturus Therapeutics：企業情報
13.8.2 Arcturus Therapeutics：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.8.3 Arcturus Therapeutics：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.8.4 Arcturus Therapeutics：主要事業概要
13.8.5 Arcturus Therapeutics：直近の展開
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim：企業情報
13.9.2 Boehringer Ingelheim：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.9.3 Boehringer Ingelheim：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.9.4 Boehringer Ingelheim：主要事業概要
13.9.5 Boehringer Ingelheim：直近の展開
13.10 Chiesi Farmaceutici
13.10.1 Chiesi Farmaceutici：企業情報
13.10.2 Chiesi Farmaceutici：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.10.3 Chiesi Farmaceutici：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.10.4 Chiesi Farmaceutici：主要事業概要
13.10.5 Chiesi Farmaceutici：直近の展開
13.11 Corbus Pharmaceuticals
13.11.1 Corbus Pharmaceuticals：企業情報
13.11.2 Corbus Pharmaceuticals：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.11.3 Corbus Pharmaceuticals：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.11.4 Corbus Pharmaceuticals：主要事業概要
13.11.5 Corbus Pharmaceuticals：直近の展開
13.12 Genzyme
13.12.1 Genzyme：企業情報
13.12.2 Genzyme：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.12.3 Genzyme：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.12.4 Genzyme：主要事業概要
13.12.5 Genzyme：直近の展開
13.13 Insmed
13.13.1 Insmed：企業情報
13.13.2 Insmed：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.13.3 Insmed：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.13.4 Insmed：主要事業概要
13.13.5 Insmed：直近の展開
13.14 Johnson & Johnson
13.14.1 Johnson & Johnson：企業情報
13.14.2 Johnson & Johnson：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.14.3 Johnson & Johnson：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.14.4 Johnson & Johnson：主要事業概要
13.14.5 Johnson & Johnson：直近の展開
13.15 Merck Sharp & Dohme
13.15.1 Merck Sharp & Dohme：企業情報
13.15.2 Merck Sharp & Dohme：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.15.3 Merck Sharp & Dohme：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.15.4 Merck Sharp & Dohme：主要事業概要
13.15.5 Merck Sharp & Dohme：直近の展開
13.16 Neovii Biotech
13.16.1 Neovii Biotech：企業情報
13.16.2 Neovii Biotech：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.16.3 Neovii Biotech：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.16.4 Neovii Biotech：主要事業概要
13.16.5 Neovii Biotech：直近の展開
13.17 Novo Nordisk
13.17.1 Novo Nordisk：企業情報
13.17.2 Novo Nordisk：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.17.3 Novo Nordisk：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.17.4 Novo Nordisk：主要事業概要
13.17.5 Novo Nordisk：直近の展開
13.18 PharmaSwiss
13.18.1 PharmaSwiss：企業情報
13.18.2 PharmaSwiss：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.18.3 PharmaSwiss：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.18.4 PharmaSwiss：主要事業概要
13.18.5 PharmaSwiss：直近の展開
13.19 Pharmaxis
13.19.1 Pharmaxis：企業情報
13.19.2 Pharmaxis：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.19.3 Pharmaxis：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.19.4 Pharmaxis：主要事業概要
13.19.5 Pharmaxis：直近の展開
13.20 Proteostasis Therapeutics
13.20.1 Proteostasis Therapeutics：企業情報
13.20.2 Proteostasis Therapeutics：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.20.3 Proteostasis Therapeutics：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.20.4 Proteostasis Therapeutics：主要事業概要
13.20.5 Proteostasis Therapeutics：直近の展開
13.21 PTC Therapeutics
13.21.1 PTC Therapeutics：企業情報
13.21.2 PTC Therapeutics：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.21.3 PTC Therapeutics：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.21.4 PTC Therapeutics：主要事業概要
13.21.5 PTC Therapeutics：直近の展開
13.22 United Medical
13.22.1 United Medical：企業情報
13.22.2 United Medical：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.22.3 United Medical：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.22.4 United Medical：主要事業概要
13.22.5 United Medical：直近の展開
13.23 Venus Remedies
13.23.1 Venus Remedies：企業情報
13.23.2 Venus Remedies：嚢胞性線維症治療薬製品ポートフォリオと特徴
13.23.3 Venus Remedies：嚢胞性線維症治療薬売上・収益・価格およびグロスマージン（2018年～2023年）
13.23.4 Venus Remedies：主要事業概要
13.23.5 Venus Remedies：直近の展開
14 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cystic Fibrosis Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis Drugs.
The global Cystic Fibrosis Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cystic Fibrosis Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cystic Fibrosis Drugs players cover Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals, Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics and Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Oral Cystic Fibrosis Drugs
Injection Cystic Fibrosis Drugs
Segmentation by application
Hospitals
Clinics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Actavis
F. Hoffmann-La Roche
Gilead Sciences
Novartis
Vertex Pharmaceuticals
Abbott
Anthera Pharmaceuticals
Arcturus Therapeutics
Boehringer Ingelheim
Chiesi Farmaceutici
Corbus Pharmaceuticals
Genzyme
Insmed
Johnson & Johnson
Merck Sharp & Dohme
Neovii Biotech
Novo Nordisk
PharmaSwiss
Pharmaxis
Proteostasis Therapeutics
PTC Therapeutics
United Medical
Venus Remedies
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cystic Fibrosis Drugs market?
What factors are driving Cystic Fibrosis Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cystic Fibrosis Drugs market opportunities vary by end market size?
How does Cystic Fibrosis Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cystic Fibrosis Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Cystic Fibrosis Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Cystic Fibrosis Drugs by Country/Region, 2018, 2022 & 2029
2.2 Cystic Fibrosis Drugs Segment by Type
2.2.1 Oral Cystic Fibrosis Drugs
2.2.2 Injection Cystic Fibrosis Drugs
2.3 Cystic Fibrosis Drugs Sales by Type
2.3.1 Global Cystic Fibrosis Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Cystic Fibrosis Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Cystic Fibrosis Drugs Sale Price by Type (2018-2023)
2.4 Cystic Fibrosis Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Other
2.5 Cystic Fibrosis Drugs Sales by Application
2.5.1 Global Cystic Fibrosis Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Cystic Fibrosis Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Cystic Fibrosis Drugs Sale Price by Application (2018-2023)
3 Global Cystic Fibrosis Drugs by Company
3.1 Global Cystic Fibrosis Drugs Breakdown Data by Company
3.1.1 Global Cystic Fibrosis Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Cystic Fibrosis Drugs Sales Market Share by Company (2018-2023)
3.2 Global Cystic Fibrosis Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Cystic Fibrosis Drugs Revenue by Company (2018-2023)
3.2.2 Global Cystic Fibrosis Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Cystic Fibrosis Drugs Sale Price by Company
3.4 Key Manufacturers Cystic Fibrosis Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cystic Fibrosis Drugs Product Location Distribution
3.4.2 Players Cystic Fibrosis Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cystic Fibrosis Drugs by Geographic Region
4.1 World Historic Cystic Fibrosis Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Cystic Fibrosis Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Cystic Fibrosis Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Cystic Fibrosis Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Cystic Fibrosis Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Cystic Fibrosis Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Cystic Fibrosis Drugs Sales Growth
4.4 APAC Cystic Fibrosis Drugs Sales Growth
4.5 Europe Cystic Fibrosis Drugs Sales Growth
4.6 Middle East & Africa Cystic Fibrosis Drugs Sales Growth
5 Americas
5.1 Americas Cystic Fibrosis Drugs Sales by Country
5.1.1 Americas Cystic Fibrosis Drugs Sales by Country (2018-2023)
5.1.2 Americas Cystic Fibrosis Drugs Revenue by Country (2018-2023)
5.2 Americas Cystic Fibrosis Drugs Sales by Type
5.3 Americas Cystic Fibrosis Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cystic Fibrosis Drugs Sales by Region
6.1.1 APAC Cystic Fibrosis Drugs Sales by Region (2018-2023)
6.1.2 APAC Cystic Fibrosis Drugs Revenue by Region (2018-2023)
6.2 APAC Cystic Fibrosis Drugs Sales by Type
6.3 APAC Cystic Fibrosis Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cystic Fibrosis Drugs by Country
7.1.1 Europe Cystic Fibrosis Drugs Sales by Country (2018-2023)
7.1.2 Europe Cystic Fibrosis Drugs Revenue by Country (2018-2023)
7.2 Europe Cystic Fibrosis Drugs Sales by Type
7.3 Europe Cystic Fibrosis Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cystic Fibrosis Drugs by Country
8.1.1 Middle East & Africa Cystic Fibrosis Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Cystic Fibrosis Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Cystic Fibrosis Drugs Sales by Type
8.3 Middle East & Africa Cystic Fibrosis Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cystic Fibrosis Drugs
10.3 Manufacturing Process Analysis of Cystic Fibrosis Drugs
10.4 Industry Chain Structure of Cystic Fibrosis Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cystic Fibrosis Drugs Distributors
11.3 Cystic Fibrosis Drugs Customer
12 World Forecast Review for Cystic Fibrosis Drugs by Geographic Region
12.1 Global Cystic Fibrosis Drugs Market Size Forecast by Region
12.1.1 Global Cystic Fibrosis Drugs Forecast by Region (2024-2029)
12.1.2 Global Cystic Fibrosis Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Cystic Fibrosis Drugs Forecast by Type
12.7 Global Cystic Fibrosis Drugs Forecast by Application
13 Key Players Analysis
13.1 Actavis
13.1.1 Actavis Company Information
13.1.2 Actavis Cystic Fibrosis Drugs Product Portfolios and Specifications
13.1.3 Actavis Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Actavis Main Business Overview
13.1.5 Actavis Latest Developments
13.2 F. Hoffmann-La Roche
13.2.1 F. Hoffmann-La Roche Company Information
13.2.2 F. Hoffmann-La Roche Cystic Fibrosis Drugs Product Portfolios and Specifications
13.2.3 F. Hoffmann-La Roche Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 F. Hoffmann-La Roche Main Business Overview
13.2.5 F. Hoffmann-La Roche Latest Developments
13.3 Gilead Sciences
13.3.1 Gilead Sciences Company Information
13.3.2 Gilead Sciences Cystic Fibrosis Drugs Product Portfolios and Specifications
13.3.3 Gilead Sciences Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Gilead Sciences Main Business Overview
13.3.5 Gilead Sciences Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Cystic Fibrosis Drugs Product Portfolios and Specifications
13.4.3 Novartis Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Vertex Pharmaceuticals
13.5.1 Vertex Pharmaceuticals Company Information
13.5.2 Vertex Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications
13.5.3 Vertex Pharmaceuticals Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Vertex Pharmaceuticals Main Business Overview
13.5.5 Vertex Pharmaceuticals Latest Developments
13.6 Abbott
13.6.1 Abbott Company Information
13.6.2 Abbott Cystic Fibrosis Drugs Product Portfolios and Specifications
13.6.3 Abbott Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Abbott Main Business Overview
13.6.5 Abbott Latest Developments
13.7 Anthera Pharmaceuticals
13.7.1 Anthera Pharmaceuticals Company Information
13.7.2 Anthera Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications
13.7.3 Anthera Pharmaceuticals Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Anthera Pharmaceuticals Main Business Overview
13.7.5 Anthera Pharmaceuticals Latest Developments
13.8 Arcturus Therapeutics
13.8.1 Arcturus Therapeutics Company Information
13.8.2 Arcturus Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications
13.8.3 Arcturus Therapeutics Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Arcturus Therapeutics Main Business Overview
13.8.5 Arcturus Therapeutics Latest Developments
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Information
13.9.2 Boehringer Ingelheim Cystic Fibrosis Drugs Product Portfolios and Specifications
13.9.3 Boehringer Ingelheim Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Boehringer Ingelheim Main Business Overview
13.9.5 Boehringer Ingelheim Latest Developments
13.10 Chiesi Farmaceutici
13.10.1 Chiesi Farmaceutici Company Information
13.10.2 Chiesi Farmaceutici Cystic Fibrosis Drugs Product Portfolios and Specifications
13.10.3 Chiesi Farmaceutici Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Chiesi Farmaceutici Main Business Overview
13.10.5 Chiesi Farmaceutici Latest Developments
13.11 Corbus Pharmaceuticals
13.11.1 Corbus Pharmaceuticals Company Information
13.11.2 Corbus Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications
13.11.3 Corbus Pharmaceuticals Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Corbus Pharmaceuticals Main Business Overview
13.11.5 Corbus Pharmaceuticals Latest Developments
13.12 Genzyme
13.12.1 Genzyme Company Information
13.12.2 Genzyme Cystic Fibrosis Drugs Product Portfolios and Specifications
13.12.3 Genzyme Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Genzyme Main Business Overview
13.12.5 Genzyme Latest Developments
13.13 Insmed
13.13.1 Insmed Company Information
13.13.2 Insmed Cystic Fibrosis Drugs Product Portfolios and Specifications
13.13.3 Insmed Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Insmed Main Business Overview
13.13.5 Insmed Latest Developments
13.14 Johnson & Johnson
13.14.1 Johnson & Johnson Company Information
13.14.2 Johnson & Johnson Cystic Fibrosis Drugs Product Portfolios and Specifications
13.14.3 Johnson & Johnson Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Johnson & Johnson Main Business Overview
13.14.5 Johnson & Johnson Latest Developments
13.15 Merck Sharp & Dohme
13.15.1 Merck Sharp & Dohme Company Information
13.15.2 Merck Sharp & Dohme Cystic Fibrosis Drugs Product Portfolios and Specifications
13.15.3 Merck Sharp & Dohme Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Merck Sharp & Dohme Main Business Overview
13.15.5 Merck Sharp & Dohme Latest Developments
13.16 Neovii Biotech
13.16.1 Neovii Biotech Company Information
13.16.2 Neovii Biotech Cystic Fibrosis Drugs Product Portfolios and Specifications
13.16.3 Neovii Biotech Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Neovii Biotech Main Business Overview
13.16.5 Neovii Biotech Latest Developments
13.17 Novo Nordisk
13.17.1 Novo Nordisk Company Information
13.17.2 Novo Nordisk Cystic Fibrosis Drugs Product Portfolios and Specifications
13.17.3 Novo Nordisk Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Novo Nordisk Main Business Overview
13.17.5 Novo Nordisk Latest Developments
13.18 PharmaSwiss
13.18.1 PharmaSwiss Company Information
13.18.2 PharmaSwiss Cystic Fibrosis Drugs Product Portfolios and Specifications
13.18.3 PharmaSwiss Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 PharmaSwiss Main Business Overview
13.18.5 PharmaSwiss Latest Developments
13.19 Pharmaxis
13.19.1 Pharmaxis Company Information
13.19.2 Pharmaxis Cystic Fibrosis Drugs Product Portfolios and Specifications
13.19.3 Pharmaxis Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Pharmaxis Main Business Overview
13.19.5 Pharmaxis Latest Developments
13.20 Proteostasis Therapeutics
13.20.1 Proteostasis Therapeutics Company Information
13.20.2 Proteostasis Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications
13.20.3 Proteostasis Therapeutics Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Proteostasis Therapeutics Main Business Overview
13.20.5 Proteostasis Therapeutics Latest Developments
13.21 PTC Therapeutics
13.21.1 PTC Therapeutics Company Information
13.21.2 PTC Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications
13.21.3 PTC Therapeutics Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 PTC Therapeutics Main Business Overview
13.21.5 PTC Therapeutics Latest Developments
13.22 United Medical
13.22.1 United Medical Company Information
13.22.2 United Medical Cystic Fibrosis Drugs Product Portfolios and Specifications
13.22.3 United Medical Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 United Medical Main Business Overview
13.22.5 United Medical Latest Developments
13.23 Venus Remedies
13.23.1 Venus Remedies Company Information
13.23.2 Venus Remedies Cystic Fibrosis Drugs Product Portfolios and Specifications
13.23.3 Venus Remedies Cystic Fibrosis Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Venus Remedies Main Business Overview
13.23.5 Venus Remedies Latest Developments
14 Research Findings and Conclusion
List of Tables Table 1. Cystic Fibrosis Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions) Table 2. Cystic Fibrosis Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions) Table 3. Major Players of Oral Cystic Fibrosis Drugs Table 4. Major Players of Injection Cystic Fibrosis Drugs Table 5. Global Cystic Fibrosis Drugs Sales by Type (2018-2023) & (K Pcs) Table 6. Global Cystic Fibrosis Drugs Sales Market Share by Type (2018-2023) Table 7. Global Cystic Fibrosis Drugs Revenue by Type (2018-2023) & ($ million) Table 8. Global Cystic Fibrosis Drugs Revenue Market Share by Type (2018-2023) Table 9. Global Cystic Fibrosis Drugs Sale Price by Type (2018-2023) & (USD/Pcs) Table 10. Global Cystic Fibrosis Drugs Sales by Application (2018-2023) & (K Pcs) Table 11. Global Cystic Fibrosis Drugs Sales Market Share by Application (2018-2023) Table 12. Global Cystic Fibrosis Drugs Revenue by Application (2018-2023) Table 13. Global Cystic Fibrosis Drugs Revenue Market Share by Application (2018-2023) Table 14. Global Cystic Fibrosis Drugs Sale Price by Application (2018-2023) & (USD/Pcs) Table 15. Global Cystic Fibrosis Drugs Sales by Company (2018-2023) & (K Pcs) Table 16. Global Cystic Fibrosis Drugs Sales Market Share by Company (2018-2023) Table 17. Global Cystic Fibrosis Drugs Revenue by Company (2018-2023) ($ Millions) Table 18. Global Cystic Fibrosis Drugs Revenue Market Share by Company (2018-2023) Table 19. Global Cystic Fibrosis Drugs Sale Price by Company (2018-2023) & (USD/Pcs) Table 20. Key Manufacturers Cystic Fibrosis Drugs Producing Area Distribution and Sales Area Table 21. Players Cystic Fibrosis Drugs Products Offered Table 22. Cystic Fibrosis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) Table 23. New Products and Potential Entrants Table 24. Mergers & Acquisitions, Expansion Table 25. Global Cystic Fibrosis Drugs Sales by Geographic Region (2018-2023) & (K Pcs) Table 26. Global Cystic Fibrosis Drugs Sales Market Share Geographic Region (2018-2023) Table 27. Global Cystic Fibrosis Drugs Revenue by Geographic Region (2018-2023) & ($ millions) Table 28. Global Cystic Fibrosis Drugs Revenue Market Share by Geographic Region (2018-2023) Table 29. Global Cystic Fibrosis Drugs Sales by Country/Region (2018-2023) & (K Pcs) Table 30. Global Cystic Fibrosis Drugs Sales Market Share by Country/Region (2018-2023) Table 31. Global Cystic Fibrosis Drugs Revenue by Country/Region (2018-2023) & ($ millions) Table 32. Global Cystic Fibrosis Drugs Revenue Market Share by Country/Region (2018-2023) Table 33. Americas Cystic Fibrosis Drugs Sales by Country (2018-2023) & (K Pcs) Table 34. Americas Cystic Fibrosis Drugs Sales Market Share by Country (2018-2023) Table 35. Americas Cystic Fibrosis Drugs Revenue by Country (2018-2023) & ($ Millions) Table 36. Americas Cystic Fibrosis Drugs Revenue Market Share by Country (2018-2023) Table 37. Americas Cystic Fibrosis Drugs Sales by Type (2018-2023) & (K Pcs) Table 38. Americas Cystic Fibrosis Drugs Sales by Application (2018-2023) & (K Pcs) Table 39. APAC Cystic Fibrosis Drugs Sales by Region (2018-2023) & (K Pcs) Table 40. APAC Cystic Fibrosis Drugs Sales Market Share by Region (2018-2023) Table 41. APAC Cystic Fibrosis Drugs Revenue by Region (2018-2023) & ($ Millions) Table 42. APAC Cystic Fibrosis Drugs Revenue Market Share by Region (2018-2023) Table 43. APAC Cystic Fibrosis Drugs Sales by Type (2018-2023) & (K Pcs) Table 44. APAC Cystic Fibrosis Drugs Sales by Application (2018-2023) & (K Pcs) Table 45. Europe Cystic Fibrosis Drugs Sales by Country (2018-2023) & (K Pcs) Table 46. Europe Cystic Fibrosis Drugs Sales Market Share by Country (2018-2023) Table 47. Europe Cystic Fibrosis Drugs Revenue by Country (2018-2023) & ($ Millions) Table 48. Europe Cystic Fibrosis Drugs Revenue Market Share by Country (2018-2023) Table 49. Europe Cystic Fibrosis Drugs Sales by Type (2018-2023) & (K Pcs) Table 50. Europe Cystic Fibrosis Drugs Sales by Application (2018-2023) & (K Pcs) Table 51. Middle East & Africa Cystic Fibrosis Drugs Sales by Country (2018-2023) & (K Pcs) Table 52. Middle East & Africa Cystic Fibrosis Drugs Sales Market Share by Country (2018-2023) Table 53. Middle East & Africa Cystic Fibrosis Drugs Revenue by Country (2018-2023) & ($ Millions) Table 54. Middle East & Africa Cystic Fibrosis Drugs Revenue Market Share by Country (2018-2023) Table 55. Middle East & Africa Cystic Fibrosis Drugs Sales by Type (2018-2023) & (K Pcs) Table 56. Middle East & Africa Cystic Fibrosis Drugs Sales by Application (2018-2023) & (K Pcs) Table 57. Key Market Drivers & Growth Opportunities of Cystic Fibrosis Drugs Table 58. Key Market Challenges & Risks of Cystic Fibrosis Drugs Table 59. Key Industry Trends of Cystic Fibrosis Drugs Table 60. Cystic Fibrosis Drugs Raw Material Table 61. Key Suppliers of Raw Materials Table 62. Cystic Fibrosis Drugs Distributors List Table 63. Cystic Fibrosis Drugs Customer List Table 64. Global Cystic Fibrosis Drugs Sales Forecast by Region (2024-2029) & (K Pcs) Table 65. Global Cystic Fibrosis Drugs Revenue Forecast by Region (2024-2029) & ($ millions) Table 66. Americas Cystic Fibrosis Drugs Sales Forecast by Country (2024-2029) & (K Pcs) Table 67. Americas Cystic Fibrosis Drugs Revenue Forecast by Country (2024-2029) & ($ millions) Table 68. APAC Cystic Fibrosis Drugs Sales Forecast by Region (2024-2029) & (K Pcs) Table 69. APAC Cystic Fibrosis Drugs Revenue Forecast by Region (2024-2029) & ($ millions) Table 70. Europe Cystic Fibrosis Drugs Sales Forecast by Country (2024-2029) & (K Pcs) Table 71. Europe Cystic Fibrosis Drugs Revenue Forecast by Country (2024-2029) & ($ millions) Table 72. Middle East & Africa Cystic Fibrosis Drugs Sales Forecast by Country (2024-2029) & (K Pcs) Table 73. Middle East & Africa Cystic Fibrosis Drugs Revenue Forecast by Country (2024-2029) & ($ millions) Table 74. Global Cystic Fibrosis Drugs Sales Forecast by Type (2024-2029) & (K Pcs) Table 75. Global Cystic Fibrosis Drugs Revenue Forecast by Type (2024-2029) & ($ Millions) Table 76. Global Cystic Fibrosis Drugs Sales Forecast by Application (2024-2029) & (K Pcs) Table 77. Global Cystic Fibrosis Drugs Revenue Forecast by Application (2024-2029) & ($ Millions) Table 78. Actavis Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 79. Actavis Cystic Fibrosis Drugs Product Portfolios and Specifications Table 80. Actavis Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 81. Actavis Main Business Table 82. Actavis Latest Developments Table 83. F. Hoffmann-La Roche Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 84. F. Hoffmann-La Roche Cystic Fibrosis Drugs Product Portfolios and Specifications Table 85. F. Hoffmann-La Roche Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 86. F. Hoffmann-La Roche Main Business Table 87. F. Hoffmann-La Roche Latest Developments Table 88. Gilead Sciences Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 89. Gilead Sciences Cystic Fibrosis Drugs Product Portfolios and Specifications Table 90. Gilead Sciences Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 91. Gilead Sciences Main Business Table 92. Gilead Sciences Latest Developments Table 93. Novartis Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 94. Novartis Cystic Fibrosis Drugs Product Portfolios and Specifications Table 95. Novartis Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 96. Novartis Main Business Table 97. Novartis Latest Developments Table 98. Vertex Pharmaceuticals Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 99. Vertex Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications Table 100. Vertex Pharmaceuticals Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 101. Vertex Pharmaceuticals Main Business Table 102. Vertex Pharmaceuticals Latest Developments Table 103. Abbott Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 104. Abbott Cystic Fibrosis Drugs Product Portfolios and Specifications Table 105. Abbott Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 106. Abbott Main Business Table 107. Abbott Latest Developments Table 108. Anthera Pharmaceuticals Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 109. Anthera Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications Table 110. Anthera Pharmaceuticals Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 111. Anthera Pharmaceuticals Main Business Table 112. Anthera Pharmaceuticals Latest Developments Table 113. Arcturus Therapeutics Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 114. Arcturus Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications Table 115. Arcturus Therapeutics Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 116. Arcturus Therapeutics Main Business Table 117. Arcturus Therapeutics Latest Developments Table 118. Boehringer Ingelheim Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 119. Boehringer Ingelheim Cystic Fibrosis Drugs Product Portfolios and Specifications Table 120. Boehringer Ingelheim Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 121. Boehringer Ingelheim Main Business Table 122. Boehringer Ingelheim Latest Developments Table 123. Chiesi Farmaceutici Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 124. Chiesi Farmaceutici Cystic Fibrosis Drugs Product Portfolios and Specifications Table 125. Chiesi Farmaceutici Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 126. Chiesi Farmaceutici Main Business Table 127. Chiesi Farmaceutici Latest Developments Table 128. Corbus Pharmaceuticals Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 129. Corbus Pharmaceuticals Cystic Fibrosis Drugs Product Portfolios and Specifications Table 130. Corbus Pharmaceuticals Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 131. Corbus Pharmaceuticals Main Business Table 132. Corbus Pharmaceuticals Latest Developments Table 133. Genzyme Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 134. Genzyme Cystic Fibrosis Drugs Product Portfolios and Specifications Table 135. Genzyme Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 136. Genzyme Main Business Table 137. Genzyme Latest Developments Table 138. Insmed Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 139. Insmed Cystic Fibrosis Drugs Product Portfolios and Specifications Table 140. Insmed Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 141. Insmed Main Business Table 142. Insmed Latest Developments Table 143. Johnson & Johnson Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 144. Johnson & Johnson Cystic Fibrosis Drugs Product Portfolios and Specifications Table 145. Johnson & Johnson Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 146. Johnson & Johnson Main Business Table 147. Johnson & Johnson Latest Developments Table 148. Merck Sharp & Dohme Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 149. Merck Sharp & Dohme Cystic Fibrosis Drugs Product Portfolios and Specifications Table 150. Merck Sharp & Dohme Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 151. Merck Sharp & Dohme Main Business Table 152. Merck Sharp & Dohme Latest Developments Table 153. Neovii Biotech Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 154. Neovii Biotech Cystic Fibrosis Drugs Product Portfolios and Specifications Table 155. Neovii Biotech Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 156. Neovii Biotech Main Business Table 157. Neovii Biotech Latest Developments Table 158. Novo Nordisk Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 159. Novo Nordisk Cystic Fibrosis Drugs Product Portfolios and Specifications Table 160. Novo Nordisk Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 161. Novo Nordisk Main Business Table 162. Novo Nordisk Latest Developments Table 163. PharmaSwiss Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 164. PharmaSwiss Cystic Fibrosis Drugs Product Portfolios and Specifications Table 165. PharmaSwiss Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 166. PharmaSwiss Main Business Table 167. PharmaSwiss Latest Developments Table 168. Pharmaxis Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 169. Pharmaxis Cystic Fibrosis Drugs Product Portfolios and Specifications Table 170. Pharmaxis Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 171. Pharmaxis Main Business Table 172. Pharmaxis Latest Developments Table 173. Proteostasis Therapeutics Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 174. Proteostasis Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications Table 175. Proteostasis Therapeutics Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 176. Proteostasis Therapeutics Main Business Table 177. Proteostasis Therapeutics Latest Developments Table 178. PTC Therapeutics Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 179. PTC Therapeutics Cystic Fibrosis Drugs Product Portfolios and Specifications Table 180. PTC Therapeutics Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 181. PTC Therapeutics Main Business Table 182. PTC Therapeutics Latest Developments Table 183. United Medical Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 184. United Medical Cystic Fibrosis Drugs Product Portfolios and Specifications Table 185. United Medical Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 186. United Medical Main Business Table 187. United Medical Latest Developments Table 188. Venus Remedies Basic Information, Cystic Fibrosis Drugs Manufacturing Base, Sales Area and Its Competitors Table 189. Venus Remedies Cystic Fibrosis Drugs Product Portfolios and Specifications Table 190. Venus Remedies Cystic Fibrosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 191. Venus Remedies Main Business Table 192. Venus Remedies Latest Developments List of Figures Figure 1. Picture of Cystic Fibrosis Drugs Figure 2. Cystic Fibrosis Drugs Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Cystic Fibrosis Drugs Sales Growth Rate 2018-2029 (K Pcs) Figure 7. Global Cystic Fibrosis Drugs Revenue Growth Rate 2018-2029 ($ Millions) Figure 8. Cystic Fibrosis Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions) Figure 9. Product Picture of Oral Cystic Fibrosis Drugs Figure 10. Product Picture of Injection Cystic Fibrosis Drugs Figure 11. Global Cystic Fibrosis Drugs Sales Market Share by Type in 2022 Figure 12. Global Cystic Fibrosis Drugs Revenue Market Share by Type (2018-2023) Figure 13. Cystic Fibrosis Drugs Consumed in Hospitals Figure 14. Global Cystic Fibrosis Drugs Market: Hospitals (2018-2023) & (K Pcs) Figure 15. Cystic Fibrosis Drugs Consumed in Clinics Figure 16. Global Cystic Fibrosis Drugs Market: Clinics (2018-2023) & (K Pcs) Figure 17. Cystic Fibrosis Drugs Consumed in Other Figure 18. Global Cystic Fibrosis Drugs Market: Other (2018-2023) & (K Pcs) Figure 19. Global Cystic Fibrosis Drugs Sales Market Share by Application (2022) Figure 20. Global Cystic Fibrosis Drugs Revenue Market Share by Application in 2022 Figure 21. Cystic Fibrosis Drugs Sales Market by Company in 2022 (K Pcs) Figure 22. Global Cystic Fibrosis Drugs Sales Market Share by Company in 2022 Figure 23. Cystic Fibrosis Drugs Revenue Market by Company in 2022 ($ Million) Figure 24. Global Cystic Fibrosis Drugs Revenue Market Share by Company in 2022 Figure 25. Global Cystic Fibrosis Drugs Sales Market Share by Geographic Region (2018-2023) Figure 26. Global Cystic Fibrosis Drugs Revenue Market Share by Geographic Region in 2022 Figure 27. Americas Cystic Fibrosis Drugs Sales 2018-2023 (K Pcs) Figure 28. Americas Cystic Fibrosis Drugs Revenue 2018-2023 ($ Millions) Figure 29. APAC Cystic Fibrosis Drugs Sales 2018-2023 (K Pcs) Figure 30. APAC Cystic Fibrosis Drugs Revenue 2018-2023 ($ Millions) Figure 31. Europe Cystic Fibrosis Drugs Sales 2018-2023 (K Pcs) Figure 32. Europe Cystic Fibrosis Drugs Revenue 2018-2023 ($ Millions) Figure 33. Middle East & Africa Cystic Fibrosis Drugs Sales 2018-2023 (K Pcs) Figure 34. Middle East & Africa Cystic Fibrosis Drugs Revenue 2018-2023 ($ Millions) Figure 35. Americas Cystic Fibrosis Drugs Sales Market Share by Country in 2022 Figure 36. Americas Cystic Fibrosis Drugs Revenue Market Share by Country in 2022 Figure 37. Americas Cystic Fibrosis Drugs Sales Market Share by Type (2018-2023) Figure 38. Americas Cystic Fibrosis Drugs Sales Market Share by Application (2018-2023) Figure 39. United States Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 40. Canada Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 41. Mexico Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 42. Brazil Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 43. APAC Cystic Fibrosis Drugs Sales Market Share by Region in 2022 Figure 44. APAC Cystic Fibrosis Drugs Revenue Market Share by Regions in 2022 Figure 45. APAC Cystic Fibrosis Drugs Sales Market Share by Type (2018-2023) Figure 46. APAC Cystic Fibrosis Drugs Sales Market Share by Application (2018-2023) Figure 47. China Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 48. Japan Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 49. South Korea Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 50. Southeast Asia Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 51. India Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 52. Australia Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 53. China Taiwan Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 54. Europe Cystic Fibrosis Drugs Sales Market Share by Country in 2022 Figure 55. Europe Cystic Fibrosis Drugs Revenue Market Share by Country in 2022 Figure 56. Europe Cystic Fibrosis Drugs Sales Market Share by Type (2018-2023) Figure 57. Europe Cystic Fibrosis Drugs Sales Market Share by Application (2018-2023) Figure 58. Germany Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 59. France Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 60. UK Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 61. Italy Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 62. Russia Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 63. Middle East & Africa Cystic Fibrosis Drugs Sales Market Share by Country in 2022 Figure 64. Middle East & Africa Cystic Fibrosis Drugs Revenue Market Share by Country in 2022 Figure 65. Middle East & Africa Cystic Fibrosis Drugs Sales Market Share by Type (2018-2023) Figure 66. Middle East & Africa Cystic Fibrosis Drugs Sales Market Share by Application (2018-2023) Figure 67. Egypt Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 68. South Africa Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 69. Israel Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 70. Turkey Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 71. GCC Country Cystic Fibrosis Drugs Revenue Growth 2018-2023 ($ Millions) Figure 72. Manufacturing Cost Structure Analysis of Cystic Fibrosis Drugs in 2022 Figure 73. Manufacturing Process Analysis of Cystic Fibrosis Drugs Figure 74. Industry Chain Structure of Cystic Fibrosis Drugs Figure 75. Channels of Distribution Figure 76. Global Cystic Fibrosis Drugs Sales Market Forecast by Region (2024-2029) Figure 77. Global Cystic Fibrosis Drugs Revenue Market Share Forecast by Region (2024-2029) Figure 78. Global Cystic Fibrosis Drugs Sales Market Share Forecast by Type (2024-2029) Figure 79. Global Cystic Fibrosis Drugs Revenue Market Share Forecast by Type (2024-2029) Figure 80. Global Cystic Fibrosis Drugs Sales Market Share Forecast by Application (2024-2029) Figure 81. Global Cystic Fibrosis Drugs Revenue Market Share Forecast by Application (2024-2029)
